2024
12430 Urine Steroid Profiling In Patients With Unilateral And Bilateral Mild Autonomous Cortisol Secretion
Salama B, Saini J, Fell V, Atkinson E, Achenbach S. 12430 Urine Steroid Profiling In Patients With Unilateral And Bilateral Mild Autonomous Cortisol Secretion. Journal Of The Endocrine Society 2024, 8: bvae163.317. PMCID: PMC11454782, DOI: 10.1210/jendso/bvae163.317.Peer-Reviewed Original ResearchMild autonomous cortisol secretionAutonomous cortisol secretionMacronodular adrenal hyperplasiaUrine steroid profileAdrenal hyperplasiaTumor bulkDehydroepiandrosterone sulfateDST cortisolBilateral macronodular adrenal hyperplasiaInterim analysis of patientsSteroid profileCortisol secretionInterim analysisSingle-center cross-sectional studyAdrenal mass sizeUrine steroid metabolomeBilateral adrenal adenomasCompared to patientsAnalysis of patientsPost-DST cortisolProfile of patientsHigh-resolution mass spectrometry assayPrevalence of comorbiditiesSteroid profile analysisPlasma steroid profiles8714 Impact of Adrenalectomy Versus Conservative Therapy On Frailty In Mild Autonomous Cortisol Secretion: A Prospective Multi-Center Cohort Study
Bassiony M, Dogra P, Šambula L, Saini J, Ambroziak U, Kastelan D, Bancos I. 8714 Impact of Adrenalectomy Versus Conservative Therapy On Frailty In Mild Autonomous Cortisol Secretion: A Prospective Multi-Center Cohort Study. Journal Of The Endocrine Society 2024, 8: bvae163.213. PMCID: PMC11454724, DOI: 10.1210/jendso/bvae163.213.Peer-Reviewed Original ResearchNonfunctioning adrenal adenomasAutonomous cortisol secretionPost-dexamethasone cortisolTreated patientsFrailty indexCortisol secretionMulti-center cohort studyCompared to patientsImpact of adrenalectomyFrailty prevalenceAdrenal adenomaPost-adrenalectomyConservative therapyMedian ageCohort studyAdrenalectomyPatientsConservative managementFrailty assessmentAdverse health outcomesPrevalenceBaselineBaseline FIHealth outcomesImproved FIThe impact of diabetes mellitus on the outcomes of revascularization for chronic limb-threatening ischemia in the BEST-CLI trial
Ochoa Chaar C, Malas M, Doros G, Schermerhorn M, Conte M, Alameddine D, Siracuse J, Yadavalli S, Dake M, Creager M, Tan T, Rosenfield K, Menard M, Farber A, Hamdan A. The impact of diabetes mellitus on the outcomes of revascularization for chronic limb-threatening ischemia in the BEST-CLI trial. Journal Of Vascular Surgery 2024, 81: 376-385.e3. PMID: 39332785, DOI: 10.1016/j.jvs.2024.09.026.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaAnkle amputationLower extremity revascularizationBEST-CLI trialBEST-CLILimb-threatening ischemiaAll-cause deathDiabetes mellitusChronic obstructive pulmonary diseaseImpact of diabetes mellitusImpact of DMObstructive pulmonary diseasePotential confoundersBest Surgical TherapyAnkleAdverse limb eventsToe pressureBest EndovascularAnkle pressureRenal diseaseAmputationObservational studyOptimal medical therapyOutcomes of patientsCompared to patientsAnticoagulation in Patients with Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization
Kim T, DeWan A, Murray M, Wang H, Mani A, Mena-Hurtado C, Guzman R, Ochoa Chaar C. Anticoagulation in Patients with Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Annals Of Vascular Surgery 2024, 105: 150-157. PMID: 38593922, DOI: 10.1016/j.avsg.2024.02.006.Peer-Reviewed Original ResearchPremature peripheral arterial diseaseAntiplatelet therapyVascular Quality InitiativeArtery diseaseAdjunct to antiplatelet therapyReturn to the operating roomPost-operative anticoagulationCompared to patientsPostoperative antiplatelet therapyOne-year outcomesCongestive heart failureLower extremity revascularizationMajor adverse limb eventsCoronary artery diseaseEffects of anticoagulantsAmputation-free survivalEarly onset of diseaseAdverse limb eventsPeripheral vascular interventionsOnset of diseasePeripheral arterial diseaseLower-extremity revascularizationPropensity score matchingPerioperative mortalityBaseline characteristics
2023
Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Lee M, Peng S, Lee A, Wong S, Tay R, Li J, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Wong M, Su Y, Alexander L, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals, Academy Of Medicine, Singapore 2023, 52: 8-16. PMID: 36730801, DOI: 10.47102/annals-acadmedsg.2022302.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinesDoses of SARS-CoV-2 mRNA vaccinesMRNA vaccinesCancer patientsThird doseHaematological malignanciesLong-term immunogenicityCompared to patientsRisk of severe diseaseAnti-neoplastic treatmentActive cancer therapyVirus neutralisation assaySARS-CoV-2 infectionSystemic chemotherapyNo patientEarly administrationSeroconversion ratesVaccine immunogenicitySolid tumorsClinical efficacyClinical outcomesSevere infectionsCancer therapyHumoral responseActive treatment
2020
Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy.
Berger Y, Schuitevoerder D, Vining C, Giurcanu M, Posner M, Roggin K, Polite B, Liao C, Eng O, Catenacci D, Turaga K. Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy. Journal Of Clinical Oncology 2020, 38: 409-409. DOI: 10.1200/jco.2020.38.4_suppl.409.Peer-Reviewed Original ResearchMetastatic gastric adenocarcinomaNational Cancer DatabaseSystemic chemotherapyOverall survivalMedian OSCytoreductive surgeryNo surgeryGastric adenocarcinomaChemotherapy-treated patientsCompared to patientsKaplan-Meier analysisClinically occult diseaseGroup of patientsCox regression modelsOS benefitTumor burdenOccult diseaseCancer DatabaseTumor-relatedImproved survivalMatched CohortChemotherapyHazard ratioProportion of diseaseM1 stage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply